Quanterix®
The Science of Precision Health



BIO 2019• June 5th 2019

Kevin Hrusovsky, Chairman & CEO

Forward-Looking Statements

This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Today's Agenda

Quanterix
The Science of Precision Health

1. Compelling Strategic and Financial Opportunity
2. Compelling Milestones Achieved with Attractive Growth Catalysts
    a. Record 2018 and Q1'19 Growth, Gross Margin and Growth Acceleration
    b. $50M Raise, New Head Quarters, China Launch, Consumable Expansion
    c. SP-X Launch for Oncology and HD-X Launch Announced for Neurology
3. Revolutionizing Drug Development and Healthcare with Precision Health

Transforming Medicine with Digital Biomarkers

Quanterix
The Science of Precision Health

Today: Invasive and Late





Tomorrow: Non-invasive and Early



Simoa Sees Health to Disease Continuum

Quanterix
The Science of Precision Health



Placement of disease categories is for illustration purposes only

Strategic Direction Remains Unchanged . . .

Capture major market opportunity through our disruptive technology

Quanterix
The Science of Precision Health



Research Market

OTAM $1B → $4B

Neuro → Onco

Diagnostic Market

OTAM $5B → $36B

LDT → IVD → DTC

Analytical Validity $

Clinical Validity $



Q1 2019 Growth Led by Consumables and Instruments



- 64% Growth, Total GM 49%, + 650bp
- High margin mix accelerating
- Consumables growth +124%



Scientific Research is Driving Brand Awareness, Performance and Utilization

Quanterix
The Science of Precision Health

PUBLICATIONS**



**Cumulative

MARKERS**



**Cumulative

ACCELERATOR



INSTRUMENTS*



*Instrument segmentation estimated based on consumables sold

CONSUMABLES



Objectives 2019

Large strides in Q1 towards securing our 2019 objectives

Quanterix
The Science of Precision Health

Neurology
<10% Penetrated

High double digit growth with high utilization

Add 25 assays and globalize

- **+70% growth**



Oncology
3x Neuro

Launch penetration in Oncology market

Immuno therapy focus

- **Launched SPX and 10 Simoa panels in Q2'19**
- **Impactful webinar, high utilization, early launch success**

Strategy
Dx via Biopharma

LDT/IVD partnerships

50 phase I, II, III trials

M&A: Ab's, Clinical Lab

- **Clinically validate Nf-L for 2nd'ary endpoint & DP**
- **Partnerships progressing**
- **Abbott blood screening**

Financials

LT Growth: 40%

Gross Margin: +300 bps

Instrument Growth: +25%

- **Revenue growth +64%**
- **Gross Margin +650 bps**
- **Instrument growth +70%**

Technology

100x sensitivity by '21 YE

New frontier of medicine

Protein Translational Modifications

- **40X defined**
- **Prototype developed**

Quanterix Product Offerings

Quanterix
The Science of Precision Health

Instruments

HD-1 / HD-X Q4'19

Floor-standing integrated

Assay prep and detection

400+ publications

SR-X

Benchtop semi-automated assay prep

SP-X Q2'19

Simoa planar assay

Benchtop semi-automated assay prep

Multiplex capabilities

Assay kits

Plate

Bead

250+ assays

Homebrew kits

Singleplex and multiplex \

Services

Accelerator

Contract research & testing

Custom assay development & reagent production

CLIA and LDT capabilities

We are Addressing a Significant Unmet Need in Drug Development

FDA Announces Office of Drug Evaluation Science - ODES

Quanterix
The Science of Precision Health

DRUG PERFORMANCE

TOXICITY

Adverse drug events are a substantial cause of Death in USA

EFFICACY



PROBABILITY OF DRUG APPROVAL

300%

increase if biomarkers are used



8.4% Goes to **25%** Approval after PHASE I

Probability of phase III approval after Phase 1 approval

VALIDATION OF SIMOA IMPACT



650 clinical trials with Simoa at single CRO



MYRIAD RBM

Blue Chip Customers

Quanterix
The Science of Precision Health

Research Institutions

Biopharma

Other

2018

SP-X Launch in Oncology

Exceptional Utilization at Key Accounts

Quanterix
The Science of Precision Health



- **5** SP-Xs sold, **+86%** growth in utilization for top 3 customers
- 10 new multiplex panels across **52** immune & oncology biomarkers
- Equivalent sensitivity with HD-1

Robust Demo Program

Q² Solutions
MedImmune
University of Denver
Harvard Medical School and Brigham and Women's Hospital
Molecular Partners
Sanofi Genzyme
Icahn School of Medicine at Mount Sinai
Novartis
UCB
Myriad RBM
PPD
Roche
Cimi Paris Centre d'Immunologie et des Maladies Infectieuses
RDL Reference Laboratory
Genentech
Amgen
Carolina BioOncology Institute Cancer Therapy & Research Center
Janssen

Launching Simoa HD-X Analyzer ahead of schedule
Delivering digital biomarker disruption that you can count on

- Taking orders, shipping Q4
- Trade-in program available

Re-engineering ultra-sensitivity, leveraging years of experience

Major productivity improvements, greater **flexibility** and **unparalleled sensitivity**

Best-in-class assay performance across a **broad assay menu** to empower biomarker research and accelerate drug development.

Regulatory Compliance – Enables 21CFR Part 11 compliance with streamlined run reports and user management

Current State of the Neurology Biomarker Field

CNS protein biomarkers are accelerating given encouragement from the FDA

Quanterix
The Science of Precision Health

Biomarker Discovery Lifecycle



Unmet Need

Development of neurological disease diagnostics has been slow due to disease complexity.



Neuro health has become national Health Priority due to veteran PTSD, opioid addictions, AD demographics mental health issues, and healthcare burden of neurological conditions

Biopharma industry discouraged by lack of returns and use of **subjective cognitive endpoints**

1. FDA issuing guidance to enable use of biomarkers in drug trials for early stage disease cohorts

2. Biopharma deploying biomarker approaches to trial design

Source: Health Advances analysis, Quanterix materials.

Neurology Momentum Fueling Growth



- Nf-L showing tremendous potential for key clinical applications in top peer-reviewed pubs; FDA interest
- Better AUC measuring AB40/42 than breakthrough device exemption for Alzheimer's
- Promise of blood-based neurology tests based on publications (CNN, Forbes, Bloomberg, Washington Post, GMA, etc.)
- Deep adoption by leading academic and pharma with strong network of world-leading KOLs

NF-L Rapidly Expanding as Best In Class Neuro Biomarker

Quanterix
The Science of Precision Health

RESEARCH PUBLICATIONS ON NFL

Three shots on goal:

- **MS:** 18k cohort normalcy trial, 17 site analytical validation
- **TBI:** Two NIH trials w/ Nf-L as co-primary endpoints
- **Alzheimer's:** Detect 16 years before dementia



46 active clinical trials using sNf-L

Genentech
A Member of the Roche Group
Lilly
Pfizer
Biogen
Roche
NOVARTIS
SANOFI
MERCK
axon NEUROSCIENCE
DENALI THERAPEUTICS

Source: Health Advances analysis, PubMed.

AAN 2019: Explosive momentum of Simoa NfL



BusinessWire
A Berkshire Hathaway Company

HOME SERVICES NEWS EDUCATION ABOUT US Search

Quanterix' Simoa Technology Powers More Than 85 Percent of Neurofilament Light Biomarker Research to be Unveiled at American Academy of Neurology Annual Meeting

Leading global neurology conference will feature 36 new Simoa-powered studies validating the use of Neurofilament light chain (Nf-L) as a potential diagnostic and prognostic biomarker for neurodegeneration

Simoa NfL
Meeting Abstracts & Presentations



5 Phase III trials across >1600 MS patients demonstrate clinical utility of Simoa NfL

Serum Neurofilament Light (NfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients: Toward Implementation Into Clinical Care.

Peter A. Calabresi,[1] Jens Kuhle,[2] Douglas L. Arnold,[3] R. Philip Kinkel,[4] Ludwig Kappos,[2] Carol M. Singh,[5] Dipen Sangurdekar,[5] Carl De Moor,[5] Bob Engle,[5] Ray Su,[5] Aaron Deykin,[5] Elizabeth Fisher,[5] Alfred Sandrock,[5] Bernd C. Kieseier,[5] Richard A. Rudick,[5] Tatiana Plavina[5]

[1]Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; [2]Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, Basel, Switzerland; [3]Montreal Neurological Institute, McGill University, Montreal, QC, Canada; [4]Department of Neurosciences, University of California, San Diego, CA, USA; [5]Biogen Inc., Cambridge, MA, USA

Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study

Raju Kapoor[1], Finn Sellebjerg[2], Hans-Peter Hartung[3], Douglas Arnold[4], Mark S. Freedman[5], Douglas Jeffery[6], Aaron Miller[7], Keith R. Edwards[8], Carol M. Singh[9], In Chang[9], Zhang Ren[9], Dipen Sangurdekar[9], Bing Zhu[9], Devangi Mehta[9], Pei-Ran Ho[9], Nolan Campbell[9], Michael Edwards[9], Elizabeth Fisher[9], Bernd C. Kieseier[9], Richard A. Rudick[9], Tatiana Plavina[9]

Long-term Effect of Fingolimod in Reducing Blood Neurofilament Light Levels in Patients with Relapsing-remitting Multiple Sclerosis

Jeffrey Cohen[1], Ludwig Kappos[2], Nadia Tenenbaum[3], Jackie Han[3], Harald Kropshofer[4], Davorka Tomic[4], Jens Kuhle[2]
[1]Cleveland Clinic, [2]Neurologic Clinic and Policlinic, Department of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, [3]Novartis Pharmaceuticals Corporation, [4]Novartis Pharma AG

Objective:
To assess the effect of long-term treatment with fingolimod on blood neurofilament light chain (NfL) levels in patients with relapsing-remitting multiple sclerosis (RRMS).
Background:
NfL, a cytoskeleton protein, is elevated in blood upon neuroaxonal damage. Blood NfL is a promising biomarker for monitoring disease activity, treatment response, and prognosis in MS.
Design/Methods:
This post hoc analysis was based on data from patients who received fingolimod 0.5 mg once daily or placebo/interferon β-1a (IFN) 30 µg once weekly in pivotal studies (24-month FREEDOMS/12-month TRANSFORMS), and then fingolimod in the open-label LONGTERMS extension study for up to 10 years. The analysis included a subset of patients who had blood NfL assessments at baseline, end of core (EoC) in pivotal studies, and end of study (EoS) in LONGTERMS. Patients were categorized into two groups: a continuous group (n=37) who received fingolimod throughout the studies and a switched group (n=42) who transitioned from placebo/IFN group to fingolimod in the LONGTERMS. NfL was measured using Single Molecule Array (SIMOA™) immunoassay. The geometric mean change in NfL levels from baseline to EoS was analyzed using Wilcoxon signed-rank test.

Results:
The mean exposure to fingolimod was 3483 days in the continuous group and 2822 days in the switched group. In the continuous group, baseline NfL levels of 33 pg/mL were significantly reduced by approximately 40% at both EoC and EoS (20 pg/mL; P<0.0001 and P=0.0002, respectively). In the switched group, baseline NfL levels of 29 pg/mL were reduced by 15% at EoC (25 pg/mL, P>0.44) and 41% at EoS (17 pg/mL, P<0.0001).
Conclusions: Fingolimod 0.5 mg significantly reduced blood NfL, maintaining its low levels with continuous treatment for up to 10 years. NfL levels were reduced to a lesser extent during treatment with IFN but decreased further with switch to fingolimod, demonstrating the greater impact of highly effective therapy in RRMS.

Emerging Clinical Biomarker: Neurofilament Light (NfL)

Quanterix
The Science of Precision Health

NFL PUBLICATIONS



STUDIES CONFIRM NFL CLINICAL UTILITY:

- Disease activity monitoring
- Drug efficacy monitoring
- Relapse/severity prognostic

Majority of published data obtained with Simoa NfL

WW DISEASE INCIDENCE (MILLIONS)



MULTIPLE SCLEROSIS:

- Avg. age of onset: 34 yrs; avg. life expectancy after onset: 30 yrs
- Standard of care: MRI 1-2X/yr
- NfL as MRI replacement: 3.5M tests/yr

Clinical Validation of NfL for MS is a Key Beachhead

Poised to Disrupt Healthcare and Create Significant Value

Quanterix
The Science of Precision Health

market

execution

Quanterix

		Differentiator	Value
1	Category-defining; Unrivaled Sensitivity / Technology	Best in Class	Disrupt
2	Methodical market penetration strategy to reward investors	$3B to $38B	New Answers
3	DNA – RNA - Protein; Better linked to Disease / Health		Holy Grail
4	**Validation**: 19/20 top pharma, PPH, 800+ trials	500+ pubs All Areas	Proven
5	Growth & Value; Razor – razor blade, $150M invested	Product Launches	Rapid Growth
6	Low Risk / Solid Return + Uber Return Prospect		Retail
7	Track Record for Commercializing Disruption		Lynchpin